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Introduction
Perinatal asphyxia, resulting in hypoxic-ischemic encephalopathy (HIE), is one of the worldwide leading causes of death and disability in children. In high-income countries 1 to 6 per 1000 newborns suffer from HIE during the perinatal period often resulting in cerebral palsy, epilepsy, visual impairment and motor-cognitive deficits in later life (Eunson, 2015) . In contrast, MSC have been shown to act on secondary injury processes and promote endogenous repair which is initiated in the post-acute phase (Ferriero, 2004; Gunn et al., 2017 ; Thornton et al., 2012) . Therefore, acute HT with delayed MSC therapy would be an attractive therapy design.
Even though small clinical trials (e.g. NCT02612155, NCT02881979), investigating the effect of stem cell therapy in cooled asphyxiated newborns, are already underway, pre-clinical studies have rarely addressed the benefit of the combined treatment. Park et al. delivered human umbilical cord blood MSC intraventricularly prior to HT, resulting in long-term protection from HIE-induced brain tissue loss (Park et al., 2015) . However, an acute intracerebral cell administration is unlikely to be feasible in the clinical setup following perinatal asphyxia. Experimental work investigating HT in combination with a less invasive and delayed stem cell therapy was lacking.
The present study investigated the hypothesis that immediate HT combined with delayed intranasal MSC therapy promotes endogenous repair mechanisms and inhibits secondary injury processes overcoming current limitations of HT for the treatment of neonatal HIE.
Materials and Methods

Isolation and culture of murine bone marrow mesenchymal stem cells
Bone marrow MSC were cultured according to previously published protocols (van Velthoven et al., 2010a). Briefly, bone marrow from femurs and tibias of 5-7 week old C57BL/6J mice (Harlan, Germany) was flushed with Dulbeccos modified eagle medium low glucose
GlutaMAX
Tm (DMEM, Gibco, Germany) /20% fetal calf serum (FCS, Biochrom, Germany).
Cells were sub-cultured four to six times prior to administration. For in vivo tracking analysis, GFP-labelled MSC (Cyagen Biosciences Inc, USA) were thawed and sub-cultured twice before intranasal delivery. Fig. S1A ). Flow cytometric analyses were performed on a BD LSRII equipped with FACS Diva Software (both BD Biosciences) which was used for acquisition and data analysis.
Osteogenic and adipogenic differentiation potential ( Supplementary Fig. S1 Fig. S1B ).
Chondrogenic differentiation potential was determined by seeding 4x10 5 cells in 15 ml Falcon tubes in duplicate to enable formation of spheroids. After 24-48 hours one sample of duplicates was exposed to chondrogenic differentiation medium (PromoCell) while MSC growth medium was used as negative control in the remaining tube. Medium was exchanged every 3 days. After incubation for 18-21 days cell pellets were carefully removed and frozen on dry ice. Cell pellets were cut into 10 µm cryostat sections and differentiation into chondrocytes was evaluated by staining with Alcian Blue (0.25%) for 5 hours ( Supplementary   Fig. S1B ).
Animal care and group allocation
Experiments were performed in accordance to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines with government approval by the State Agency for Nature, Environment and Consumer Protection North Rhine-Westphalia. C57BL/6J mice were bred in house and kept under a 12 hours light/dark cycle with food and water ad libitum. Animals subjected to behavioral testing were weaned at postnatal day 21 (P21) and housed in groups of 4-5 animals per cage. Bodyweight was recorded at P10, P11, P12, P16 and once a week after weaning.
A total of 305 P9 pups (n=151 female and n=154 male) derived from 41 litters were enrolled.
Forty seven mice underwent sham surgery. Out of the 258 animals exposed to hypoxiaischemia 18 animals (7%) died immediately after or during hypoxia. Temperature during intervention was monitored in sentinel pups (n=42 in total, Supplementary Fig. S2A ), being excluded from data analysis to minimize confounding effects by stressful temperature measurements. Remaining animals were randomly assigned to 4 treatment groups by an independent scientist not involved in data acquisition: (1) hypoxia ischemia (HI)/normothermia (NT, n=18 (5 weeks survival), n=16 (1 week survival), n=8 (4 days survival), n=8 (3 days survival)), (2) HI/hypothermia (HT, n=20 (5 weeks survival), n=14 (1 week survival), n=8 (4 days survival), n=8 (3 days survival)), (3) HI/NT/MSC (MSC, n=17 (5 weeks survival), n=16 (1 week survival), n=16 (4 days survival)) (4) HI/HT/MSC (HT+MSC, n=18 (5 weeks survival), n=15 (1 week survival), n=16 (4 days survival)). In total 1 NT and 1 HT+MSC died within the first week after HI; 2 HT and 2 HT+MSC animals died between 1 and 5 weeks post injury induction. Experimenters were blinded to all interventions and data analysis.
Neonatal hypoxia-ischemia
Hypoxic-ischemic (HI) brain injury was induced as previously described (Reinboth et al., 2016) . Briefly, the right common carotid artery was occluded through cauterization (high temperature cauter, 1200°C, Bovie, USA) under isoflurane anesthesia (1.5-4 Vol%, total duration of surgery: 5-7 minutes) followed by one hour hypoxia (10% O 2 ) in an air-tight oxygen chamber (OxyCycler, Biospherix, USA) after one hour recovery with their dams.
According to our previous study where we identified a physiological body core (i.e. nesting) temperature of 35°C for P9 mice (Reinboth et al., 2016) animals were placed on a warming mat (Harvard Apparatus, USA) to maintain nesting temperature during hypoxia. Shamoperated animals received anesthesia and neck incision only.
Therapeutic hypothermia and MSC-treatment
According to our previous study, HT was applied immediately following HI for 4 hours with a target temperature of T rectal 32°C (Reinboth et al., 2016) . Mice were placed on a custommade plate with temperature control by water circulation. Controls (NT) were placed on a warming mat to maintain physiological body core temperature (T rectal 35°C) conforming to our previous work (Reinboth et al., 2016) . Three days after HI (Fig. 1A) , a total of 1x10 6 MSC or vehicle (0.9% sodium chloride) were administered intranasally as previously described 
Long-term functional outcome
Behavioral assessment was performed according to our previously described protocols (Reinboth et al., 2016) . Shortly, exploration and impulsive behavior was assessed in the elevated plus maze (Lister, 1987 with 2 identical objects in two facing corners. The animals were returned to their cages for an inter-trial interval of 30 minutes. In the following retention/test trial, animals were exposed to one familiar object and one novel object replacing the second familiar object in the arena.
Novel object activity was recorded for 5 minutes.
From P21 onwards, animals were transferred to an inversed 12 hours light/dark cycle and behavioral testing was initiated at P44 (Reinboth et al., 2016) . It started with one day of elevated plus maze followed by one day open field and one day novel object recognition test.
Data were recorded using an automatic tracking system (Video-Mot2, TSE Systems, Germany) and exported for statistical analysis. All experimental procedures were carried out in the dark phase in a dimly lit (red light) and a low noise environment (behavioral unit).
Tissue preparation, histology and immunohistochemistry
One week after HI, mice were deeply anesthetized with chloralhydrate (200 mg/kg body weight) and transcardially perfused with ice-cold phosphate buffered saline (PBS). Brains anti-rat Alexa Fluor 488, both: 1:500, Invitrogen, Germany) for 2 hours at room temperature.
Nuclei were counterstained with 4',6-Diamidin-2-phenylindol (Dapi, 100 ng/ml; Molecular Probes, USA).
Quantification of neuronal, oligodendrocyte and vessel density; vessel diameters and peripheral leukocyte infiltration
Defined non-overlapping regions of interest (ROI, each 189000 µm² (CD45, CD31) and 45900 µm 2 (NeuN, Olig2)) were visualized by fluorescence microscopy (20x and 40x
objective; Axioplan; Zeiss, Germany) connected to a CCD camera (Axiocam ICc1, Zeiss).
For representative images, low and high magnification images were acquired with confocal microscopy (A1plus, Eclipse Ti, with NIS Elements AR software, Nikon, Germany). At the level of the striatum 6 defined non-overlapping ROI were analyzed in each hemisphere (3 ROI in the cortex and 3 ROI in the striatum). At the level of the hippocampus 10 ROI (3 ROI in the cortex, 4 ROI in the hippocampus and 3 ROI in the thalamus) were evaluated in each
hemisphere. Oligodendrocytes and vessels were counted manually on acquired images.
Since single cell counting could not be applied in densely packed regions of neurons or strong leukocyte infiltration (e.g. hippocampus), images were converted into binary images followed by measurement of NeuN and CD45 positive areas using Image J (NIH, USA).
Ipsilateral vessel diameters were measured with Image J for 12-15 randomly selected vessels per animal derived from three non-overlapping hippocampal ROI (CA1, CA2, DG covering a total area of 0.567 mm²).
Western Blot
For western blot analysis sections of 200 µm thickness of the ipsilateral hemisphere within the range of 0.3 to 0 mm from bregma (striatal level) and -2.0 to -2.3 mm from bregma (hippocampal level) were dissected and homogenized in ice-cold lysis buffer (RIPA, SigmaAldrich) containing protease and phosphatase inhibitors (cOmplete, Roche) and 100 mM PMSF (Sigma-Aldrich). The supernatant was collected and processed as previously suspension for flow cytometry analysis was performed as previously described (Herz et al., 2014) . Hemispheres were dissected, cerebellum removed followed by homogenization through a 70 μm cell strainer (BD Biosciences, Germany) during continuous rinsing with 15 ml of cold HEPES-buffered RPMI1640. Two hemispheres were pooled per sample to avoid potential cell loss through tissue processing. Samples were centrifuged at 400×g for 10 minutes at 18 °C. The supernatants were discarded and the pellets were re-suspended in 37% Percoll followed by centrifugation at 2800×g for 20 minutes. Myelin was removed and the remaining cell pellet was washed twice in PBS. Total cell counts were determined using BD TrueCount beads (BD Biosciences). Viable cells were quantified by adding 1 µg/ml propidium iodide immediately prior to measurement. Data acquisition and analysis were performed on a BD FACS LSRII equipped with FACS Diva software (BD Biosciences).
MSC co-culture with brain extracts and gene expression analysis
MSC were cultured with brain extracts as previously described (van Velthoven et al., 2010b).
Tissues of ipsilateral hemispheres (+0.5 to -2.3 mm from bregma) of mice from all treatment groups were dissected on ice followed by homogenization in knock-out DMEM (Gibco).
Supernatants were stored at -80°C until use. One million MSC/well were pre-cultured in 6-well plates for 24 hours in DMEM/20% FCS followed by culture in DMEM knock out medium supplemented with isolated brain extract (1 mg protein/ml medium). Fig. S2A ). HI animals revealed significantly reduced body weight gain compared to shamoperated animals early after HI independent of treatment ( Supplementary Fig. S2B ).
Confounding effects on neurobehavioral assessment by different weight gain could be excluded because no significant differences were observed across all experimental groups 5 weeks after HI ( Supplementary Fig. S2B ).
Exploratory and impulsive behavior, analyzed by elevated plus maze, demonstrated that both single therapies (HT and MSC treatment) reduced HI-induced alterations with no significant differences compared to sham-operated control mice (Fig. 1B) . However, combined Fig. 3B ). HT significantly improved vertical activity, as a measure of motor function, which was diminished after combination with MSC therapy (Fig. 1C) .
Cognitive function, evaluated by novel object recognition was reduced in NT mice and was not recovered by HT. However, MSC significantly improved long-term cognitive function (Fig.   1D ), being reversed when HT preceded treatment leading to a significantly reduced novel object activity compared to sham controls (Fig. 1D) .
Combining acute hypothermia with delayed MSC treatment diminishes early neuroprotection
To assess whether the observed detrimental interaction was initiated early after combining both treatments, we analyzed histopathological, cellular and structural grey and white matter injury at one week post HI.
Total and local hippocampal injury was significantly reduced by both, HT and MSC (Fig. 2) .
After combining both treatments, protective effects were decreased resulting in significantly increased injury scores of HT+MSC compared to single MSC therapy for total and local injury within the hippocampus (Fig. 2) . In cortex and striatum, HT-and MSC-induced significant protection was reversed after combined treatment ( Supplementary Fig. S4A, B) . In the thalamus, all administered therapies revealed similar protection ( Supplementary Fig. S4C ).
For further insight into target structures with respect to sub-acute grey and white matter injury, western blot analyses for MAP-2 and MBP expression at the level of the striatum and the hippocampus were performed. NT animals demonstrated a marked loss of both axonal and myelin structures in ipsilateral hemispheres (Fig. 3) . Whereas HT significantly improved expression of MAP-2 expression, MSC treatment did not have an effect on axonal degeneration (Fig. 3) . In contrast, myelination assessed by quantification of MBP expression was significantly improved by MSC treatment but not by HT (Fig. 3) . Interestingly, combination of HT and MSC resulted in a significant improvement of MAP-2 expression at the hippocampal level, whereas enhanced myelination by MSC was abolished in animals treated with HT before MSC administration (Fig. 3) .
To analyze whether differential effects on structural damage might be attributed to cellular loss or differentiation deficits, we quantified neuronal and oligodendrocyte density via immunohistochemistry for NeuN and Olig2. The most pronounced reduction of neuronal density was observed in the hippocampus and striatum, which was ameliorated by single HT and MSC treatment (Fig. 4A,B) . However, after combining both therapies the single therapyeffects were diminished resulting in no significant differences compared to NT animals ( Fig.   4A,B) . While neuronal density is decreased, HI induced a significant increase in oligodendrocytes in most severely affected brain regions (i.e. striatum, hippocampus) which was not modulated by HT, MSC or combined treatment (Fig. 4C,D) .
Anti-inflammatory effects of acute hypothermia and delayed MSC treatment are reversed after combined treatment
To dissect the underlying mechanisms of opposite effects by the combined treatment, we analyzed sub-acute neuroinflammatory responses. HT, MSC and the combination of both demonstrated a marked down-regulation of microglia activation assessed by Iba-1 protein expression (Fig. 5A ). As these results may not explain the detrimental interaction of both therapies, we analyzed peripheral leukocyte infiltration and endothelial activation. Whereas HT and MSC inhibited HI-induced infiltration of leukocytes, animals exposed to the combined treatment showed an increased leukocyte infiltration with no significant differences compared to normothermic controls (Fig. 5B ). Similar to these results, HI-induced up-regulation of the endothelial adhesion molecule VCAM-1 in NT animals was significantly reduced by HT and MSC (Fig. 5C ), which was reversed after combining both therapies (Fig. 5C ). Whether increased VCAM-1 expression was caused by general modulation of vascular integrity was examined by evaluation of blood vessel density and diameters. HI-induced vessel loss and dilation was improved by all therapeutic interventions (Fig. 5D) .
MSC home to HI-injured brains independent of treatment
To investigate whether observed effects might have been caused by impaired MSC homing in HT-treated animals we quantified GFP-labelled MSC in brains of NT and HT-treated animals 14-16 hours after intranasal delivery. These analyses revealed a huge interindividual variation, which was, however, independent of treatment ( Supplementary Fig.   S5A ,B) suggesting a similar migratory behavior of MSC in NT and HT animals. Of note, no GFP-positive cells were detected in contralateral hemispheres ( Supplementary Fig. S5A ).
Overall cell number was low implicating that MSC may also have been distributed to organ systems thereby potentially mediating systemic effects. Therefore, we measured blood plasma cytokine levels for all experimental groups demonstrating no significant alteration by injury or therapy for TNFalpha and IL-10 while slightly increased levels of IL-4 in NT animals were significantly reduced by single MSC therapy and the combined treatment with HT ( Supplementary Fig. S5C ). However, no differences were detected between MSC and HT+MSC treated animals, thus not explaining interaction effects for HI-induced brain injury.
Modulation of MSC phenotype after culture with brain extracts of hypothermia-treated animals
According to a similar homing of MSC to injured hemispheres in NT and HT treated animals we hypothesized that MSC change their phenotype due to the changed in vivo microenvironment in cooled animals. Therefore, we analyzed gene expression in MSC for cytokines and growth factors in MSC, co-cultured with conditioned medium containing brain extracts obtained from P12 mice exposed to sham operation, HI+NT or HI+HT on P9 (Fig.   6A ). In response to culture with HT-brain homogenate, MSC up-regulated pro-inflammatory cytokine expression (e.g. IL-1beta and IL-6) while expression of the anti-inflammatory cytokine IL-10 was reduced compared to co-culture with brain extracts derived from NTtreated control mice (Fig. 6B) . Furthermore, NT-brain homogenates led to increased growth factor expression (e.g. BDNF and EGF) which was significantly reduced after incubation with brain extracts obtained from HT-treated animals (Fig. 6B) . Analysis of cell culture supernatants to determine protein secretion by MSC partially confirmed mRNA analysis demonstrating reduced levels of IL-10 and IGF in HT-brain homogenate co-cultures compared to NT-brain co-cultures (Fig. 6C ). For few analyses (e.g. BDNF and TNFalpha) no significant differences were observed, most likely due to the simultaneous time point of analysis, i.e. transcriptional regulation preceding complex processes of protein translation and intracellular targeting for extracellular secretion. Medium containing brain extracts at culture concentration (1 mg/ml) without cells demonstrated cytokine and growth factor concentrations below the detection limit, thus not confounding results of these analyses.
Combination of hypothermia and delayed MSC therapy increases pro-inflammatory cytokines and reduces neurotrophic factor levels in HI-injured brains
To verify in vitro results cytokine and growth factor levels were analyzed in brain tissue lysates 24 hours after intranasal administration of MSC or vehicle in NT and HT-treated animals. These analyses partially confirmed in vitro data, e.g. IL-6 and IL-1beta levels were increased by the combination of HT and MSC compared to single therapies (Fig. 7A) . For IL-10 slightly increased levels in single treatments were reduced by HT+MSC though not reaching significance (Fig. 7A) . Growth factor concentrations (except for VEGF) were increased to abnormal high levels by HI but normalized to control levels by HT and MSC single therapy, while the combined treatment induced a further decline below control levels (Fig. 7B) . Of note, VEGF is down-regulated by HI and improved by HT, MSC but also by the combination (Fig. 7B) .
Discussion
The present study shows that acute hypothermia (HT) following neonatal hypoxia-ischemia These results suggest that MSC exposed to the anti-inflammatory environment induced by HT, may increase inflammation. This is supported by our in vitro analyses, demonstrating that MSC exposed to HT brain extracts increase expression of pro-inflammatory cytokines Regional neuronal and oligodendrocyte densities were determined in cortex, striatum, hippocampus and thalamus of P16 mice exposed to HI followed by 4 hours NT or HT on P9.
MSC were administered intranasally at P12. MSC were cultured for 48 hours with brain extracts obtained from P12 mice that were  Acute hypothermia (HT) improves motor deficits after neonatal hypoxiaischemia (HI).
 Delayed intranasal MSC therapy protects from HI-induced cognitive dysfunction.
 Improved motor-cognitive function by HT and MSC is reduced after combination.
 Acute HT with delayed MSC therapy after HI diminishes sub-acute neuroprotection.
 Decreased neuro-inflammatory responses by HT and MSC are increased after combination.
